Eikon Therapeutics, Inc.
EIKNEikon Therapeutics is a late-stage clinical biopharmaceutical company that integrates advanced engineering and super-resolution microscopy with traditional drug discovery.
Earnings
Next report
Aug 10, 2026 (Today)Competitors
By market cap
By revenue growth
Profile
Eikon Therapeutics is a late-stage clinical biopharmaceutical company that integrates advanced engineering and super-resolution microscopy with traditional drug discovery. The company utilizes its proprietary single molecule tracking (SMT) platform to monitor protein dynamics in living cells, aiming to develop novel therapies for oncology and neurological diseases. Its strategy combines internally developed programs with opportunistic in-licensing of promising clinical assets.
Eikon is a pioneer in applying Nobel Prize-winning super-resolution microscopy to drug discovery, led by a management team with a significant track record in oncology commercialization.
FAQ
- What is Eikon Therapeutics, Inc.'s market cap?
- Eikon Therapeutics, Inc. (EIKN) has a market capitalization of $498.6M and trades on XNAS.
- Who are Eikon Therapeutics, Inc.'s competitors?
- Eikon Therapeutics, Inc.'s key competitors include IDEAYA Biosciences, Gilead Sciences, Inhibrx Biosciences, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Eikon Therapeutics, Inc. partner with?
- Eikon Therapeutics, Inc.'s notable partners include Merck & Co., Seven and Eight Biotherapeutics Corp., Impact Therapeutics (Shanghai) Inc., and others.
- Where is Eikon Therapeutics, Inc. headquartered?
- Eikon Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2026.